Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
The latest update is out from Paragon 28 ( (FNA) ).
Paragon 28 has announced the appointment of Dave Demski as an independent director, expanding its Board of Directors to nine members. Demski brings over two decades of executive leadership experience in the medical device industry, having previously served as President and CEO of Globus Medical. His appointment is expected to bolster Paragon 28’s strategic oversight and governance capabilities, further supporting its mission to advance foot and ankle patient care. This move signals a strengthening of Paragon 28’s position in the orthopedic market, potentially enhancing its innovation and impact on patient lives globally.
More about Paragon 28
Paragon 28, Inc., based in Englewood, CO, is a leading medical device company specializing in the foot and ankle orthopedic market. The company is dedicated to improving patient outcomes through innovative solutions for various foot and ankle ailments, including fracture fixation and progressive collapsing foot deformity. Paragon 28 designs its products with both patients and surgeons in mind, aiming to enhance procedural outcomes and reduce complications.
YTD Price Performance: -15.53%
Average Trading Volume: 571,351
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $879.1M
See more data about FNA stock on TipRanks’ Stock Analysis page.
